• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Tango Therapeutics Inc.

    4/17/26 7:42:24 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNGX alert in real time by email
    DEFA14A 1 d93491ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    TANGO THERAPEUTICS, INC.

    (Name of registrant as specified in its charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


     

     

     

     

    TANGO THERAPEUTICS, INC.

    201 BROOKLINE AVENUE, SUITE 901

    BOSTON, MA 02215

     

     

    V90761-P50670

     

        

     

    LOGO

     

     

    You invested in TANGO THERAPEUTICS, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on June 4, 2026.

    Get informed before you vote

    View the Notice and Proxy Statement and Annual Report online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting them prior to May 21, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

    LOGO

    *Please check the meeting materials for any special requirements for meeting attendance.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote on these important matters.

     

     Voting Items       

    Board

    Recommends

     
     1.    Election of Class II Directors    
     
       Company Nominees:       
     

     1a.

       Malte Peters, M.D.        LOGO  

    For

     

     1b.

       Kanishka Pothula        LOGO  

    For

     

     1c.

       Mace Rothenberg, M.D.        LOGO  

    For

     
     2.    To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.   LOGO  

    For

     
     3.    To approve, on a non-binding, advisory basis, the compensation of our named executive officers.   LOGO  

    For

    NOTE: The Board of Directors will consider and act upon such other business as may properly come before the meeting or any adjournment or postponement thereof.

           
       

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

    V90762-P50670

    Get the next $TNGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNGX

    DatePrice TargetRatingAnalyst
    4/3/2026$30.00Buy
    Canaccord Genuity
    4/2/2026$30.00Buy
    Canaccord Genuity
    2/23/2026$19.00Outperform
    Mizuho
    11/18/2025Peer Perform
    Wolfe Research
    8/19/2025$11.00Overweight
    Piper Sandler
    7/17/2024$19.00Buy
    Jefferies
    4/4/2024Overweight
    Cantor Fitzgerald
    2/12/2024$18.00Overweight
    Piper Sandler
    More analyst ratings

    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $30.00

    4/3/26 10:44:59 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $30.00

    4/2/26 8:13:25 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Tango Therapeutics with a new price target

    Mizuho initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $19.00

    2/23/26 8:40:01 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    11/18/24 7:20:03 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4) (Amendment)

    4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 7:41:18 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boxer Capital, Llc bought $8,722,500 worth of shares (1,250,000 units at $6.98) (SEC Form 4)

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    10/17/23 6:04:34 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

    -  Matthew Gall appointed Chief Financial Officer  --  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced key leadership appointments, adding three seasoned industry executives to the Company to support the rapid advancement of vopimetostat, a highly potent and selective PRMT5 inhibitor, towards its first potential regulatory approval in pancreatic cancer. Matthew Gall has been appointed Chief Financial O

    4/15/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

    VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science. That capital is not spreading evenly: it is concentrating on precision medicine, where the global oncology precision medicine market is projected to reach $303 billion by 2035[2], growing at approximately 9% annually as targeted cancer treatments move from promising idea to standard care. The five companies in thi

    3/19/26 11:00:00 AM ET
    $ATOS
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The options have an exercise price of $

    3/6/26 5:33:52 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Crystal Adam

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    4/16/26 8:14:04 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Crystal Adam

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    4/2/26 8:09:07 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Crystal Adam

    4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

    3/27/26 8:06:56 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Tango Therapeutics Inc.

    DEFA14A - Tango Therapeutics, Inc. (0001819133) (Filer)

    4/17/26 7:42:24 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Tango Therapeutics Inc.

    DEF 14A - Tango Therapeutics, Inc. (0001819133) (Filer)

    4/17/26 7:12:25 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

    4/15/26 9:19:28 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Leadership Updates

    Live Leadership Updates

    View All

    Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

    Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement with Erasca, plus ongoing Revolution Medicines collaboration, supports potential of vopimetostat as the preferred PRMT5 inhibitor for combination with RAS targeted therapies in oncology Cash position of $343 million as of December 31, 2025, with runway into 2028 beyond anticipated key data inflection points BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the n

    3/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

    Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company's founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a

    1/8/26 9:05:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Appoints Sung Lee to Board of Directors

    BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Mr. Sung Lee to the Board of Directors. Mr. Lee has over 20 years of experience in finance leadership in the biopharmaceutical and technology industries. "We are delighted to welcome Sung Lee to our Board of Directors," said Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics. "Sung's proven track record in corporate strategy, investor relations and finance will be instrumental as we advance our lead program, vopimetostat, into reg

    1/5/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tango Therapeutics Inc.

    SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/20/24 4:24:26 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    11/7/24 9:35:56 PM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tango Therapeutics Inc.

    SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

    10/28/24 9:22:40 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TNGX
    Financials

    Live finance-specific insights

    View All

    Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

    BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast link here Barclays 28th Annual Global Healthcare Conference, Miami Hosting 1x1 meetings on Tuesday, March 10 2026 Leerink Partners Global Healthcare Conference, Miami Fireside chat

    2/18/26 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

    BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cance

    10/29/25 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

    – 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% –  – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 –  – 49% ORR and mPFS 9.1 months in histology agnostic cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity – – Company to hold conference call today at 8:30am ET –  BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive data from its ongoing Phase 1/2 stud

    10/23/25 7:00:00 AM ET
    $TNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care